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Intermittent Preventive Treatment in Pregnancy With 
Sulfadoxine–Pyrimethamine: The Controversy Continues
Julie Gutman
Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and 
Prevention, Atlanta, Georgia
Each year, approximately 32 million pregnancies occur in malaria-endemic areas of Africa 
[1]. Malaria in pregnancy (MiP) is a serious condition that contributes to both maternal and 
infant morbidity and mortality. It is estimated that up to 200 000 infant deaths occur 
annually as a result of MiP (http://www.who.int/features/2003/04b/en/). In order to decrease 
the risk of Plasmodium falciparum infection in pregnancy and subsequent morbidity and 
mortality, the World Health Organization (WHO) recommends intermittent preventive 
treatment in pregnancy (IPTp) with at least 2 doses of sulfadoxine-pyrimethamine (SP) 1 
month apart after quickening. As resistance of Plasmodium falciparum, the most important 
malaria species in MiP, to SP has increased in the past 2 decades with a concomitant 
decrease in the efficacy of SP for treatment of children <5 years of age, the continued 
benefit of providing IPTp-SP has been questioned [2]. IPTp-SP continues to provide benefit 
to mothers and infants in areas where the rate of treatment failure in children is up to 39% 
[3]; however, where treatment failure rates are higher, and when coverage with insecticide-
treated bednets is high, IPTp-SP appears to provide less benefit [4, 5]. More worrisome are 
data from Muheza, Tanzania, suggesting that IPTp-SP may be harmful, exacerbating 
placental malaria and contributing to fetal anemia [6, 7]. If this finding is replicated in other 
areas, it will have significant implications, as it would suggest that the practice of providing 
IPTp-SP to women in areas with high levels of SP resistance should be discontinued 
immediately, rather than continuing this practice until an alternate drug for prophylaxis in 
pregnancy is found.
In this issue of Clinical Infectious Diseases, Rogawski et al provide reassuring data from a 
large retrospective delivery cross-sectional study in Malawi that IPTp-SP is not associated 
with fetal anemia or cord hemoglobin concentration [8]. There was no evidence that this 
lack of association changed over time as SP resistance increased. Furthermore, their data 
suggest that IPTp-SP continues to provide some beneficial effect, as evidenced by the 
finding that malaria parasitemia at delivery had the largest effect on fetal anemia among 
primigravid women who did not take SP and no significant effect among multigravid 
women whether or not they took SP. This is consistent with what has been reported 
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previously; IPTp-SP has been shown to be beneficial in primigravid and secundigravid 
women, but it remains unclear whether there is a benefit to women of higher gravidity [9]. 
The fact that IPTp-SP may still confer some benefit to primigravid women in Malawi is an 
important finding, especially in light of the fact that Malawi has high levels of molecular 
resistance to SP, with nearly 100% saturation of quintuple mutants, although mutations such 
as dhps 581 or dhfr 164, which are associated with higher level SP resistance, are still rare 
[10]. This suggests that although it is necessary to explore alternative therapies to IPTp-SP, 
it need not be abandoned yet.
It is important to note that other studies that have examined the issue of fetal anemia 
following maternal SP use have also found that IPTp-SP decreases, not increases, the 
prevalence of fetal anemia [5, 11]. The reason for the discrepancy between these studies and 
the study conducted in Muheza may have to do with the extremely high level of resistance 
found in the Muheza area, with 14-day treatment failure rates in children of 68% (no recent 
studies in children have been done in Malawi to compare with this) or with the relatively 
higher proportion of dhps 581 mutations in Muheza than can be found in other study sites. 
The data from Muheza suggesting that SP is responsible for the fetal anemia are convincing: 
cord sulfa concentration was found to inversely correlate with cord hemoglobin levels. 
However, of the 880 women studied, cord samples for sulfa analysis were available from 
847 and IPTp-SP history was available from 826, but only 685 are used in the analysis of 
fetal hemoglobin. It is unclear how this subset was identified for analysis, and whether this 
could have affected the results.
Another issue to consider in future studies examining the effectiveness of IPTp-SP is which 
women should be included. Initial studies of IPTp-SP focused on primigravid and 
secundigravid women, as they have the least pregnancy-specific malaria immunity, and so 
are at the greatest risk [12]. As insecticide-treated bednet coverage and other malaria 
interventions are scaled up and transmission declines, it is likely that the effects of MiP will 
increasingly be seen in women of higher gravidity. However, if we really want to evaluate 
whether IPTp-SP continues to reduce the burden of MiP, we should choose the women most 
likely to benefit and exclude multigravid women, otherwise we run the risk of diluting our 
ability to observe an effect.
It is clear that in areas of high level SP resistance, IPTp-SP no longer provides the same 
degree of benefit that it once did, and that it is imperative to search for alternatives to 
prevent MiP [4, 5]. SP can be given as a single dose, it is extremely cost-effective, and there 
is a long experience of its use in pregnancy showing it to be safe. As the currently available 
best options (mefloquine, dihydroartemisinin-piperaquine, and azithromycin-chloroquine) 
are certainly much more expensive than SP, it remains to be seen how feasible it will be to 
implement any of these at scale across sub-Saharan Africa. In addition, of these options, 
only mefloquine can possibly be given as a single dose (and it is unclear whether mefloquine 
as a single dose will be tolerated by the majority of pregnant women), thus directly observed 
therapy administered at antenatal clinics will no longer be a practical option. Given the 
difficulties with the other options, IPTp-SP should be continued as long as it provides 
benefit, ideally with 3 doses delivered during the course of pregnancy [13]. Countries where 
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SP is used for IPTp should prioritize monitoring SP resistance using the standardized 
protocol, to allow for a change in policy when IPTp-SP ceases to be beneficial.
Despite the fact that most sub-Saharan African countries have high antenatal clinic 
attendance and have had a written policy recommending IPTp-SP since 2004, coverage of 2 
doses remains woefully inadequate (<60% in the majority of countries) [14]. Various factors 
have been proposed to explain this, including stock-outs of SP, confusion among healthcare 
workers about when SP is safe and when to give it, and multiple versions of guidelines in 
countries indicating different recommendations. It is likely that the continued debate over 
the safety and efficacy of IPTp-SP contributes to a lack of political will and traction for 
promoting what ought to be a very simple intervention.
Intermittent screening and treatment during pregnancy (ISTp) is an alternative strategy 
comprising a rapid diagnostic test at each antenatal clinic visit and treatment of only those 
women who test positive. This has the benefit of exposing only those women who actually 
have malaria to a drug, thus limiting the risks of adverse effects. An initial study in Ghana 
which looked at ISTp-SP and ISTp with amodiaquine plus artesunate compared with IPTp-
SP suggests that this may be a promising strategy, but further studies looking at additional 
drugs and settings are needed before this can be widely recommended [15]. Until such a 
time as a feasible alternative to IPTp-SP exists, and as long as there is evidence of some 
beneficial effect, a clarification of the guidelines with a change to recommend provision of 
IPTp-SP at each antenatal clinic visit could go a long way toward increasing coverage of this 
intervention.
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